Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides
DermatologyResearch Phase

Decorinyl (Tripeptide-10 Citrulline)

Topical
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Decorinyl is a modified tripeptide featuring citrulline substitution, engineered to interact with decorin, a small leucine-rich proteoglycan that regulates collagen fibrillogenesis. The peptide is proposed to enhance decorin production and activity in the dermis, thereby promoting organized collagen assembly and tensile strength.

Mechanism of Action

Its development targets improvement of dermal structural integrity in aging and photoaged skin.

Research Summary & Key Findings

Preclinical fibroblast culture assays have shown upregulation of decorin mRNA and improved alignment of collagen fibrils in three-dimensional matrix models. Clinical validation through randomized controlled trials has not been published in major dermatology journals as of recent literature reviews.

Clinical Status

Research Phase

Decorinyl (Tripeptide-10 Citrulline) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Topical

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Dermatology

No lawful pathway today

Decorinyl (Tripeptide-10 Citrulline) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.